Abstract
Protein Tyrosine kinases (TKs) play important roles in regulating the most fundamental cell processes, such as the cell cycle, proliferation, differentiation, motility, and cell death or survival. In many tumor cells, key TKs may no longer be adequately controlled, and excessive phosphorylation sustains signal transduction pathways in an activated state. Imatinib mesylate is an oral multitargeted tyrosine kinase inhibitor with antitumor activity. It recently received approval from the US Food and Drug Administration for the treatment of patients with BCR/ABL translocation defining chronic myeloid leukaemia, and subsequently for the treatment of patients with KIT (CD117)-positive non-resectable and/or metastatic malignant gastrointestinal stromal tumors. It has also shown promising clinical activity against other advanced solid tumors. The review provides an updated summary of emerging clinical experience with this promising new anticancer agent.
Keywords: Tyrosine kinases, imatinib mesylate, targeted-therapy, ABL-BRL, c-kit, solid tumors
Current Enzyme Inhibition
Title: Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Volume: 3 Issue: 4
Author(s): Carlo Smirne, Anna Carbone, Tiziana Scirelli and Graziella Bellone
Affiliation:
Keywords: Tyrosine kinases, imatinib mesylate, targeted-therapy, ABL-BRL, c-kit, solid tumors
Abstract: Protein Tyrosine kinases (TKs) play important roles in regulating the most fundamental cell processes, such as the cell cycle, proliferation, differentiation, motility, and cell death or survival. In many tumor cells, key TKs may no longer be adequately controlled, and excessive phosphorylation sustains signal transduction pathways in an activated state. Imatinib mesylate is an oral multitargeted tyrosine kinase inhibitor with antitumor activity. It recently received approval from the US Food and Drug Administration for the treatment of patients with BCR/ABL translocation defining chronic myeloid leukaemia, and subsequently for the treatment of patients with KIT (CD117)-positive non-resectable and/or metastatic malignant gastrointestinal stromal tumors. It has also shown promising clinical activity against other advanced solid tumors. The review provides an updated summary of emerging clinical experience with this promising new anticancer agent.
Export Options
About this article
Cite this article as:
Smirne Carlo, Carbone Anna, Scirelli Tiziana and Bellone Graziella, Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions, Current Enzyme Inhibition 2007; 3 (4) . https://dx.doi.org/10.2174/157340807782330246
DOI https://dx.doi.org/10.2174/157340807782330246 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Naphthoflavones as Antiproliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1
Anti-Cancer Agents in Medicinal Chemistry The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry Phytochemical Profiles, Antioxidant and Antibacterial Activities of 11 Phellinus Mushrooms Collected in Thailand
The Natural Products Journal Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Natural Products as a Source of Protein Kinase Activators and Inhibitors
Current Topics in Medicinal Chemistry